Compare Abbott Laboratories (ABT) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs GoPro Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while GoPro Inc trades at $0.75 (market cap $121.79M). The key difference: Abbott Laboratories is far larger — about 1370.7× GoPro Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| ABT | GPRO | |
|---|---|---|
Market Cap | $166.94B | $121.79M |
Sector | Health | Technology |
52-Week High | $136.62 | $2.88 |
52-Week Low | $82.57 | $0.64 |
Enterprise Value | $193.69B | $169.74M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GoPro (GPRO) trades at $0.701, down 3.96% for the day, reflecting persistent financial distress. The stock shows a bearish technical outlook with negative cash flows and consecutive earnings misses. Recent news highlights a strategic review for potential sale or merger, announced on May 11, 2026, following weak Q1 2026 results. Revenue has declined from $1.1B in 2022 to $652M in 2025, with net losses deepening, indicating significant operational challenges.
The investment outlook remains highly speculative. The strategic sale process offers a potential catalyst, but substantial risks include ongoing cash burn, negative equity, and competitive pressures. Analyst sentiment is mixed with a cautious hold bias. Investors should weigh the binary outcome of a successful strategic transaction against the company's fundamental deterioration and explicit going-concern risks noted in recent disclosures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
